This clinical trial is focused on studying the effects of a medication called Halneuron, which contains the active substance tetrodotoxin. The study is being conducted to understand how this medication affects the body’s ability to sense things, particularly in relation to pain. Tetrodotoxin is administered as a solution for injection under the skin, and the trial involves giving healthy volunteers different doses of this medication.
The main purpose of the study is to evaluate how the peripheral nervous system, which is the part of the nervous system outside the brain and spinal cord, responds to the medication. This is done using a method called Quantitative Sensory Testing (QST), which measures how the body senses things like touch, temperature, and pain. The study will look at changes in these sensory measurements after the medication is given.
Participants in the study will receive two different doses of Halneuron and will undergo sensory testing to see how their responses change. The study will also compare the effects of the two doses and monitor any side effects that may occur. The goal is to gather information on how tetrodotoxin affects sensory perception and to ensure its safety for future use in managing pain.
The Netherlands 
